

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT COOPERATION AGREEMENT IN RELATION TO CROSS-BORDER BNCT CLINICAL SERVICES

On 2 September 2026, Pengbo (Hainan) BNCT Hospital, the Group's flagship BNCT project, entered into the Cooperation Agreement with OncoCare, a member institution of Tamarind Health, to build a cross-border oncology collaboration covering BNCT clinical services, two-way patient referral, joint multidisciplinary team consultations and post-treatment follow-up, under an "offshore assessment, onshore treatment and offshore follow-up" model.

The cooperation is intended to broaden the overseas patient pipeline for BNCT services at the Hospital and to establish a cross-border service loop leveraging the pilot medical policies of the Boao Lecheng International Medical Tourism Pilot Zone and OncoCare's screening, referral and follow-up capabilities.

This announcement is a voluntary announcement made by China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

BACKGROUND

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 2 September 2026, Pengbo (Hainan) Medical Technology Co., Ltd.* (鵬博(海南)硼中子醫療科技有限公司), a subsidiary of the Company operating under the business name of Pengbo (Hainan) BNCT Hospital (the “**Hospital**”), being the flagship boron neutron capture therapy (“**BNCT**”) project of the Group located in the Boao Lecheng International Medical Tourism Pilot Zone of Hainan Province, the People’s Republic of China (the “**PRC**”), entered into a framework cooperation agreement (the “**Cooperation Agreement**”) with OncoCare Medical Hong Kong Limited (“**OncoCare**”), a comprehensive oncology specialist institution in Hong Kong and a member institution of Tamarind Health Group (“**Tamarind Health**”), for collaboration on cross-border medical services, two-way referral, and related service cooperation for tumour patients.

THE COOPERATION AGREEMENT

Pursuant to the Cooperation Agreement, the Hospital and OncoCare will establish a cross-border oncology cooperation mechanism and may refer eligible patients in both directions. OncoCare is responsible, on the overseas side, for compliant education and disclosure, preliminary screening, cross-border referral coordination, entry and treatment guidance, and overseas postoperative rehabilitation and follow-up. The Hospital is responsible for BNCT clinical treatment, inpatient management, medical quality and safety during hospitalisation, and timely synchronisation of treatment progress to OncoCare. The parties will also conduct joint multidisciplinary team (MDT) consultations for pre-screened patients.

The Cooperation Agreement is a framework agreement with a term of one year from the date of signing, renewable by negotiation. Specific implementation arrangements, including any overseas physician practice and detailed joint-treatment rules, are subject to a separate implementation agreement.

INFORMATION ON ONCOCARE AND TAMARIND HEALTH

OncoCare is a comprehensive oncology specialist institution in Hong Kong. It provides a full spectrum of cancer care including radiotherapy, targeted therapy, immunotherapy and in-clinic chemotherapy, as well as related specialist surgical and care services. OncoCare is a member institution of Tamarind Health, an integrated oncology-focused healthcare group with a network spanning Singapore, Chinese Mainland, Hong Kong, Malaysia, the Philippines and Vietnam.

INFORMATION ON THE HOSPITAL

The Hospital, the Group’s flagship project located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the PRC, commenced trial operations in February 2026, and began patient treatment for the first time in March 2026 with dozens of treatments completed to date. Its approved indications are principally head and neck cancers, with planned expansion to other solid tumours. BNCT is a precision radiotherapy modality characterised by high tumour targeting and relatively limited damage to surrounding normal tissue. As disclosed by the Company’s announcement dated 3 August 2026 in relation to the Hospital’s clinical treatment progress, the overall response rate of the first 10 patients with head and neck cancers who received BNCT services in the Hospital reached 80%, based on a three-month follow-up after treatment.

REASONS FOR AND BENEFITS OF THE COOPERATION AGREEMENT

The Group has previously entered into cooperation agreements with well-known hospitals such as Beijing United Family Hospital Management Co., Ltd.* (北京和睦家醫院管理有限公司) in the Chinese Mainland, thereby expanding its patient pipeline in the PRC market. The Cooperation Agreement will further enable the Group to broaden the patient pipeline for BNCT services at the Hospital through OncoCare's screening, referral and follow-up capabilities, combined with Tamarind Health's oncology network in Hong Kong and other Asia-Pacific markets, and to establish a cross-border service loop of "offshore assessment, onshore treatment and offshore follow-up" by leveraging the pilot medical policies of the Boao Lecheng International Medical Tourism Pilot Zone. The Cooperation Agreement may also facilitate access by appropriate patients to subsequent rehabilitation or other oncology services in Hong Kong and other markets covered by the OncoCare and Tamarind Health network, thereby enabling the Group to expand from the PRC market to the broader Asian market.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

* for identification purposes only

Hong Kong, 2 September 2026

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.